| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rutin, a Quercetin Glycoside Rutin, a natural flavonoid glycoside found in many plants like buckwheat, citrus fruits, and apples, has shown promising neuroprotective and anticancer properties. Rutin is a flavonoid glycoside composed of quercetin bound to the disaccharide rutinose. It is widely found in buckwheat, citrus fruits, apples, and tea. In cancer models, rutin exhibits antioxidant, anti-inflammatory, anti-proliferative, and pro-apoptotic effects. Because it is glycosylated, rutin itself has relatively low cellular permeability; many biological effects are mediated after intestinal hydrolysis to quercetin and subsequent phase-II metabolites. Mechanistically, rutin is most consistently associated with suppression of NF-κB and PI3K/AKT signaling, modulation of MAPK pathways, redox regulation (Nrf2/ROS balance), inhibition of angiogenesis (VEGF), and induction of cell-cycle arrest and apoptosis in preclinical systems. Effects are model-dependent and often concentration-dependent, with antioxidant behavior dominating in normal tissue contexts and context-dependent pro-oxidant effects described in some tumor settings. -Scavenges free radicals, reduces oxidative stress -Inhibits pro-inflammatory cytokines like IL-1β, TNF-α, and reduces activation of NF-κB. -Inhibition of Aβ Aggregation (AD) -Mild inhibitory effects on acetylcholinesterase (AChE), helping enhance cholinergic function. -May upregulate BDNF expression Cancer: -Induces cell cycle arrest in G2/M phase. -Inhibits VEGF, Suppresses MMP-2 and MMP-9 -Inhibits PI3K/Akt/mTOR, MAPK, and NF-κB signaling pathways. -Enhances sensitivity to Chemotherapy drugs like doxorubicin and cisplatin Rutin has poor oral bioavailability, but this can be improved with nanoformulations or co-administration with absorption enhancers like piperine or quercetin. Cancer Pathway Table: Rutin
TSF: P = 0–30 min (rapid redox interactions), R = 30 min–3 hr (acute signaling shifts), G = >3 hr (gene-regulatory adaptation and phenotype outcomes).
Alzheimer’s Disease (AD) Summary — RutinRutin has been studied in preclinical neurodegeneration models for its antioxidant, anti-inflammatory, and mitochondrial-protective properties. It is reported to modulate Nrf2 signaling, suppress NF-κB–mediated neuroinflammation, reduce oxidative stress, and attenuate amyloid-β–induced neuronal injury in experimental systems. Many effects may be mediated after hydrolysis to quercetin. Human clinical evidence remains limited.Alzheimer’s Disease Table: Rutin
TSF: P = 0–30 min (early signaling modulation), R = 30 min–3 hr (stress-response shifts), G = >3 hr (gene-regulatory and neuroprotective outcomes). |
| Source: |
| Type: |
| Also known as CP32. Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death. As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression. Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy. Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent. On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer. Procaspase-3 is a apoptotic marker protein. Prognostic significance: • High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers. • Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers. |
| 7954- | RT, | Rutin : therapeutic potential and recent advances in drug delivery |
| - | Review, | Nor, | NA | - | Review, | IBD, | NA |
| 7951- | RT, | BuckWS, | The anticancer potential of the dietary polyphenol rutin: Current status, challenges, and perspectives |
| - | Review, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:143 Target#:42 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid